SCHEMBL713639

SCHEMBL713639

O=C(c1ccccc1)c1ccc(NS(=O)(=O)c2cccc(-c3ccc(F)cc3)c2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PGR P06401 2/20 0.64
BRD4 O60885 1/20 0.64
ITGB1 P05556 1/20 0.63
ITGA2 P17301 1/20 0.63
PFKFB3 Q16875 3/20 0.62
KAT6A Q92794 1/20 0.57
L3MBTL1 Q9Y468 1/20 0.55
ITGA1 P56199 1/20 0.54
MEN1 O00255 1/20 0.54
KMT2A Q03164 1/20 0.54
STING1 Q86WV6 1/20 0.53
PLAU P00749 1/20 0.52
HDAC2 Q92769 2/20 0.51
HDAC8 Q9BY41 2/20 0.51
HDAC6 Q9UBN7 2/20 0.51
MAPT P10636 1/20 0.51
HDAC3 O15379 1/20 0.51
HDAC4 P56524 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC7 Q8WUI4 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13631973 0.96 PGR (0.57) PGRBRD4ITGB1ITGA2PFKFB3
SCHEMBL8242878 0.92 PFKFB3 (0.71) PGRBRD4ITGB1ITGA2PFKFB3
SCHEMBL13631972 0.90 LMNA (0.59) PGRBRD4ITGB1ITGA2PFKFB3
SCHEMBL8278220 0.87 PGR (0.62) PGRPFKFB3KAT6AMEN1KMT2A
SCHEMBL13631957 0.86 MAP2K4 (0.66) PFKFB3L3MBTL1MEN1KMT2AHDAC2
SCHEMBL4183795 0.86 MAP2K4 (0.66) PGRPFKFB3KAT6AL3MBTL1STING1
SCHEMBL7805558 0.85 IDH2 (0.61) PGRPFKFB3KAT6AMEN1KMT2A
SCHEMBL788070 0.84 PFKFB3 (0.83) PFKFB3KAT6AMEN1KMT2AMAPT
SCHEMBL13631970 0.83 LIMK2 (0.54) PGRPFKFB3KAT6AL3MBTL1PLAU
SCHEMBL13631971 0.82 PGR (0.54) PGRPFKFB3KAT6AL3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120052057-A9 METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS BIOTIE THERAPIES CORPORATION (FI) 2012-03-01 US claimed
US-20110150859-A1 METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS BIOTIE THERAPIES CORPORATION (FI) 2011-06-23 US claimed
EP-2140029-A2 A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS Biotie Therapies Corp. (FI) 2010-01-06 EP claimed
WO-2008125738-A2 A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS BIOTIE THERAPIES CORPORATION (FI) 2008-10-23 WO claimed
US-20210070866-A1 Pharmaceutical Composition For Preventing Or Treating Tissue Adhesion Comprising Integrin a2ß1 Inhibitors KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) 2021-03-11 US disclosed
US-20120052057-A9 METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS BIOTIE THERAPIES CORPORATION (FI) 2012-03-01 US disclosed
US-20110150859-A1 METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS BIOTIE THERAPIES CORPORATION (FI) 2011-06-23 US disclosed
EP-2140029-A2 A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS Biotie Therapies Corp. (FI) 2010-01-06 EP disclosed
US-20090286713-A9 Collagen Receptor I-Domain Binding Modulators BIOTIE THERAPIES CORPORATION (FI) 2009-11-19 US disclosed
US-20090286713-A9 Collagen Receptor I-Domain Binding Modulators BIOTIE THERAPIES CORPORATION (FI) 2009-11-19 US disclosed
US-20090023735-A1 Sulphonamide Derivatives BIOTIE THERAPIES CORP. (FI) 2009-01-22 US disclosed
US-20090023735-A1 Sulphonamide Derivatives BIOTIE THERAPIES CORP. (FI) 2009-01-22 US disclosed
WO-2008125738-A2 A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS BIOTIE THERAPIES CORPORATION (FI) 2008-10-23 WO disclosed
US-20080255028-A1 Collagen Receptor I-Domain Binding Modulators BIOTIE THERAPIES CORPORATION (FI) 2008-10-16 US disclosed
US-20080255028-A1 Collagen Receptor I-Domain Binding Modulators BIOTIE THERAPIES CORPORATION (FI) 2008-10-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023735-A1 Sulphonamide Derivatives HCAR1, ADGRE5, ALK PGR 1226/4885BRD4 1064/4885ITGB1 19/4885
US-20080255028-A1 Collagen Receptor I-Domain Binding Modulators COL14A1, COL2A1, COL1A1 PGR 848/4885BRD4 713/4885ITGB1 8/4885
US-20090286713-A9 Collagen Receptor I-Domain Binding Modulators COL14A1, COL2A1, COL1A1 PGR 848/4885BRD4 713/4885ITGB1 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.